BioNTech SE Chief Executive Officer Ugur Sahin filed a Form 4 with the SEC on September 8, 2026, disclosing the sale of 76,500 ordinary shares across two transactions on September 3 and September 4, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • First sale: 45,000 ordinary shares disposed of on September 3, 2026, at a price of $102.8496 per share.
  • Second sale: 31,500 ordinary shares disposed of on September 4, 2026, at a price of $103.5182 per share.
  • Remaining ownership: Following both transactions, Sahin directly beneficially owned 781,709 ordinary shares, according to the filing.
  • Trading plan: Both sales were effected pursuant to a Rule 10b5-1 trading plan established by Sahin on June 3, 2026.
  • Reporting person roles: Sahin is identified in the filing as Chief Executive Officer and a 10% owner of BioNTech SE (NASDAQ:BNTX).

Details of Ugur Sahin's September 2026 Share Disposals at BioNTech SE

According to the Form 4 filed on September 8, 2026, BioNTech SE (NASDAQ:BNTX) Chief Executive Officer Ugur Sahin disposed of a combined 76,500 ordinary shares over two consecutive trading days. The filing identifies Sahin as both CEO and a 10% owner of the company. Both transactions are coded as sales ("S") and are classified as direct ownership disposals.

On September 3, 2026, the filing reports that Sahin sold 45,000 ordinary shares at $102.8496 per share, reducing his directly held position to 813,209 shares. The following day, September 4, 2026, an additional 31,500 ordinary shares were sold at $103.5182 per share, bringing his directly held beneficial ownership to 781,709 ordinary shares following the reported transactions, as disclosed in the filing.

The filing notes that "the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person on June 3, 2026." The form was signed by Humza Bokhari as Attorney-in-Fact on September 8, 2026. No derivative securities transactions were reported. Table II of the filing contains no entries.

What Was Disclosed

The filing discloses two open-market sales of BioNTech SE ordinary shares by CEO Ugur Sahin on September 3 and September 4, 2026, totaling 76,500 shares, conducted under a Rule 10b5-1 plan established June 3, 2026, with 781,709 shares remaining directly held afterward.